Overview

A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with spasticity due to spinal cord injury
Phase:
Phase 2
Details
Lead Sponsor:
Indivior Inc.
XenoPort, Inc.
Treatments:
Arbaclofen placarbil
Baclofen